Previous Article | Next Article ![]()
Infection and Immunity, May 1999, p. 2491-2496, Vol. 67, No. 5
Channing Laboratory1
and Division of Infectious Disease,
Received 18 November 1998/Returned for modification 3 February
1999/Accepted 18 February 1999
The alpha C protein, a protective surface protein of group B
streptococci (GBS), is present in most non-type III GBS strains. Conjugate vaccines composed of the alpha C protein and type III capsular polysaccharide (CPS) might be protective against most GBS
infections. In this study, the type III CPS was covalently coupled to
full-length, nine-repeat alpha C protein (resulting in III-
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Alpha C Protein as a Carrier for Type III Capsular
Polysaccharide and as a Protective Protein in Group B
Streptococcal Vaccines
9r
conjugate vaccine) or to two-repeat alpha C protein (resulting in
III-
2r conjugate vaccine) by reductive amination. Initial
experiments with the III-
9r vaccine showed that it was poorly
immunogenic in mice with respect to both vaccine antigens and was
suboptimally efficacious in providing protection in mice against
challenge with GBS. Therefore, modified vaccination protocols were used
with the III-
2r vaccine. Female mice were immunized three times with
0.5, 5, or 20 µg of the III-
2r vaccine with an aluminum hydroxide
adjuvant and bred. Ninety-five percent of neonatal mice born to dams
immunized with the III-
2r vaccine survived challenge with GBS
expressing type III CPS, and 60% survived challenge with GBS
expressing wild-type (nine-repeat) alpha C protein; 18 and 17%,
respectively, of mice in the negative control groups survived
(P, <0.0001). These protection levels did not differ
significantly from those obtained with the type III CPS-tetanus toxoid
conjugate vaccine and the unconjugated two-repeat alpha C protein,
which protected 98 and 58% of neonates from infection with GBS
expressing type III CPS or the alpha C protein, respectively. Thus, the
two-repeat alpha C protein in the vaccine was immunogenic and
simultaneously enhanced the immunogenicity of type III CPS. III-
vaccines may be alternatives to GBS polysaccharide-tetanus toxoid
vaccines, eliciting additional antibodies protective against GBS infection.
*
Corresponding author. Mailing address: Channing
Laboratory, 181 Longwood Ave., Boston, MA 02115. Phone: (617) 525-2677. Fax: (617) 731-1541. E-mail:
lmadoff{at}channing.harvard.edu.
Infection and Immunity, May 1999, p. 2491-2496, Vol. 67, No. 5
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»